K2M Group (NASDAQ:KTWO) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

Other analysts also recently issued research reports about the stock. Cowen set a $28.00 price objective on shares of K2M Group and gave the stock a “buy” rating in a research report on Thursday, August 17th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $28.00 price objective on shares of K2M Group in a research report on Tuesday, October 10th. UBS reaffirmed a “buy” rating and set a $24.00 price objective (down previously from $26.00) on shares of K2M Group in a research report on Tuesday, October 10th. William Blair reaffirmed an “outperform” rating on shares of K2M Group in a research report on Tuesday, October 10th. Finally, Needham & Company LLC reaffirmed a “strong-buy” rating and set a $27.00 price objective (down previously from $29.00) on shares of K2M Group in a research report on Monday, October 9th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $24.40.

K2M Group (NASDAQ:KTWO) traded up $0.11 during trading hours on Wednesday, reaching $17.19. 589,517 shares of the company’s stock were exchanged, compared to its average volume of 270,781. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.06 and a quick ratio of 1.67. K2M Group has a twelve month low of $16.44 and a twelve month high of $25.99.

K2M Group (NASDAQ:KTWO) last released its earnings results on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $62.65 million for the quarter, compared to analyst estimates of $62.69 million. K2M Group had a negative net margin of 16.22% and a negative return on equity of 16.02%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.19) EPS. sell-side analysts expect that K2M Group will post -0.86 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of KTWO. Teachers Advisors LLC lifted its stake in K2M Group by 3.0% during the 1st quarter. Teachers Advisors LLC now owns 43,823 shares of the medical device company’s stock valued at $899,000 after acquiring an additional 1,286 shares in the last quarter. Legal & General Group Plc lifted its stake in K2M Group by 9.1% during the 1st quarter. Legal & General Group Plc now owns 6,763 shares of the medical device company’s stock valued at $138,000 after acquiring an additional 564 shares in the last quarter. Vanguard Group Inc. lifted its stake in K2M Group by 13.8% during the 1st quarter. Vanguard Group Inc. now owns 1,379,090 shares of the medical device company’s stock valued at $28,285,000 after acquiring an additional 167,036 shares in the last quarter. Geode Capital Management LLC lifted its stake in K2M Group by 10.7% during the 1st quarter. Geode Capital Management LLC now owns 275,498 shares of the medical device company’s stock valued at $5,650,000 after acquiring an additional 26,578 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in K2M Group by 5.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 131,780 shares of the medical device company’s stock valued at $2,703,000 after acquiring an additional 7,152 shares in the last quarter. 99.16% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “K2M Group (KTWO) Downgraded by BidaskClub to “Hold”” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/10/k2m-group-ktwo-downgraded-by-bidaskclub-to-hold.html.

About K2M Group

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Analyst Recommendations for K2M Group (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.